Status:
COMPLETED
Long-term Clinical and Echographic Follow-up (More Than 4 Years) After TAVI.
Lead Sponsor:
University Hospital, Montpellier
Conditions:
Severe and Symptomatic Aortic Stenosis
Eligibility:
All Genders
18+ years
Brief Summary
Transcatheter Aortic Valve Implantation (TAVI) is became the gold-standard therapy for patients with severe and symptomatic aortic stenosis with high operative risk or not suitable for surgery. All s...
Detailed Description
Transcatheter Aortic Valve Implantation (TAVI) is became the gold-standard therapy for patients with severe and symptomatic aortic stenosis with high operative risk or not suitable for surgery. All s...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- All consecutive patients admitted from February 2010 to December 2014 at the University Hospital of Montpellier for the implantation of TAVI will be included for TAVI Edwards.
- Male or non-pregnant female ≥ 18 years without superior limit of age for TAVI, indicated for severe and sympto-matic aortic valve stenosis, defined according to the guidelines (1), with high-surgical risk or not suitable for surgery, and after Heart Team decision.
- Informed consent obtained at enrolment into the study
- Exclusion criteria:
- Inability to give informed consent or high likelihood of being unavailable for follow-up
- Patients died during the implantation and within one year after implantation will be excluded because of impossibil-ity of follow-up.
Exclusion
Key Trial Info
Start Date :
January 31 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
178 Patients enrolled
Trial Details
Trial ID
NCT03402724
Start Date
January 31 2018
End Date
December 31 2019
Last Update
April 3 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295